Striving for Consensus: Current and Future Management of Non-Small Cell Lung Cancer with an EGFR Mutation

Om avsnittet

Dr Pasi Jänne from the Dana-Farber Cancer Institute in Boston, Massachusetts, Prof Tom John from the Peter MacCallum Cancer Centre in Melbourne, Australia, Dr Zofia Piotrowska from Massachusetts General Hospital in Boston, Massachusetts, and Dr Alexander Spira from the Virginia Cancer Specialists Research Program in Fairfax, discuss recent updates on available and emerging treatment strategies for non-small cell lung cancer with an EGFR mutation.

Om avsnittet

Fler avsnitt

Non-Small Cell Lung Cancer — A Presentation by Dr Julia Rotow on the Potential Role of PD-1 x VEGF Bispecific Antibodies

Lung Cancer — Proceedings from a Symposium Held in Conjunction with the American Oncology Network

For Oncology Nurses: Non-Small Cell Lung Cancer with a ROS1 Fusion — An Interview with Dr Alexander E Drilon

Non-Small Cell Lung Cancer — Targeting KRAS G12C

Lambert-Eaton Myasthenic Syndrome in Small Cell Lung Cancer — An Interview with Prof Ticiana Leal

Small Cell Lung Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances in Therapeutic Targets Beyond EGFR

HER2-Altered Non-Small Cell Lung Cancer — 5-Minute Journal Club: Microlearning Activity 3

HER2-Altered Non-Small Cell Lung Cancer — 5-Minute Journal Club: Microlearning Activity 2

EGFR-Mutated Non-Small Cell Lung Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting